Bank of America just raised its EUR/USD forecast
Phreesia, Inc. (NYSE:PHR), a healthcare software company with a market capitalization of $1.66 billion and impressive revenue growth of ~20% over the last twelve months, saw its Chief Financial Officer Balaji Gandhi recently execute a notable sale of company stock. According to a recent SEC filing, Gandhi sold a total of 5,867 shares over two days, February 18 and 19, 2025. The shares were sold at prices ranging from $30.00 to $30.0428, amounting to a total transaction value of approximately $176,256. The sale occurred as the stock trades near its 52-week high of $30.53. InvestingPro analysis shows the company is currently slightly undervalued, with analysts projecting profitability this year.
These sales were conducted under a pre-established Rule 10b5-1 trading plan, which Gandhi had adopted on September 17, 2024. Following these transactions, Gandhi retains direct ownership of 105,418 shares of Phreesia stock. For deeper insights into PHR’s valuation and growth prospects, including 8 additional exclusive ProTips, check out the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Phreesia Inc . reported its latest quarterly earnings, surpassing expectations with an earnings per share (EPS) of -$0.25, compared to a forecast of -$0.27. The company’s revenue also exceeded projections, reaching $106.8 million against an anticipated $106.25 million. Phreesia achieved positive free cash flow for the first time, highlighting its financial progress. Analyst firms have shown confidence in Phreesia’s future, with RBC Capital Markets upgrading the stock from Sector Perform to Outperform and raising the price target to $32.00, citing strong potential for margin expansion. Piper Sandler also raised its price target to $33 while maintaining an Overweight rating, emphasizing the company’s strategic investments and expected EBITDA improvements by fiscal year 2026. Meanwhile, Baird adjusted its price target to $30.00 from $34.00, maintaining an Outperform rating, following Phreesia’s announcement of a 17% year-over-year revenue growth. These developments indicate a positive outlook for Phreesia as it continues to execute its growth strategies and improve its financial metrics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.